Search for: "SANOFI-PHARMACEUTICALS, INC." Results 41 - 60 of 214
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Jun 2020, 11:30 pm by Schachtman
” Now the claims here are quite unsettling, especially considering that they were lodged in a defense brief, in an MDL, with many cases at stake, made on behalf of an important pharmaceutical company, represented by two large, capable national or international law firms. [read post]
17 May 2020, 2:57 am by Anastasiia Kyrylenko
Kat Friend Matt Swinn shed light on a complex case between the Commonwealth of Australia and the pharmaceutical manufacturer Sanofi. [read post]
3 Mar 2020, 4:00 am by Alan Macek
In Novartis Pharmaceuticals Canada Inc. v. [read post]
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan… [read post]
30 Jan 2020, 5:29 am by Brenda Fulmer
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
30 Jan 2020, 5:29 am by Brenda Fulmer
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
11 Apr 2019, 10:59 am by Camilla Hrdy
The compounds of the present invention can be combined with pharmaceutical carriers and administered in a variety of well-known pharmaceutical forms suitable for oral or parental administration to provide compositions useful in the treatment of cardiovascular disorders and particularly mammalian hypertension. (35) (citing Sanofi v Apotex/ramipril). [read post]
20 Jun 2018, 4:12 am by Simon Holzer
Note that Meyerlustenberger Lachenal AG has been involved in this matter on behalf of Gilead) The Swiss dispute in a nutshell The Swiss litigation is about the validity of Gilead Sciences Inc. [read post]
5 Feb 2018, 9:59 pm by Patent Docs
Mylan Pharmaceuticals, Inc. v. [read post]
5 Sep 2017, 7:45 am by Ben Vernia
According to DOJ’s press release: Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today. [read post]
25 Aug 2017, 7:02 am by Fraud Fighters
On Thursday, August 17, 2017, the Department of Justice, announced that Mylan Inc. and Mylan Specialty L.P. [read post]
25 Aug 2017, 7:02 am by Fraud Fighters
On Thursday, August 17, 2017, the Department of Justice, announced that Mylan Inc. and Mylan Specialty L.P. [read post]
10 Oct 2016, 2:59 pm by Michael Grossman
Taxotere: The Case Against a Chemo Drug Taxotere, the marketed brand name of the drug docetaxel, is a taxane-class drug manufactured by Sanofi-Aventis Pharmaceutical. [read post]
26 Jul 2016, 8:45 pm by Patent Docs
Zydus Pharmaceuticals (USA) Inc. 1:16-cv-00540; filed June 29, 2016 in the District Court of Delaware Plaintiffs: Genzyme Corp.; Sanofi-Aventis U.S. [read post]